Biodesix (NASDAQ:BDSX) Releases Quarterly Earnings Results, Meets Expectations

Biodesix (NASDAQ:BDSX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07), RTT News reports. The business had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 369.89%. During the same quarter in the prior year, the business earned ($0.12) EPS. Biodesix updated its FY 2024 guidance to EPS.

Biodesix Stock Performance

Shares of NASDAQ:BDSX opened at $1.39 on Tuesday. Biodesix has a 52 week low of $1.15 and a 52 week high of $2.21. The firm's fifty day moving average is $1.71 and its 200-day moving average is $1.61. The company has a current ratio of 3.28, a quick ratio of 3.28 and a debt-to-equity ratio of 0.99.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Craig Hallum started coverage on Biodesix in a research report on Friday, July 26th. They issued a "buy" rating and a $3.00 target price on the stock. Scotiabank assumed coverage on Biodesix in a report on Monday, September 16th. They issued a "sector outperform" rating and a $3.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Biodesix has an average rating of "Buy" and an average target price of $3.06.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.